3DM Inc. to Present on Orthopedic Biomaterials at the Dow Jones Venturewire Healthcare Ventures Conference

Cambridge , Mass. – August 1, 2005 – 3DM Inc. will present to healthcare investors at the Dow Jones Venturewire Healthcare Conference, taking place in Silicon Valley on September 27-28, 2005. Zen Chu, President & Co-founder of 3DM Inc., will lend a presentation entitled “Emerging Biomaterials in Orthopedic Regenerative Medicine Applications.”

“We are honored to be asked to return to another Dow Jones conference to lend our perspective of leading edge therapies and materials for orthopedic applications where natural and artificial defects need to fill with new normal bone and cartilage,” stated Mr. Chu. “Our work in orthopedic biomaterials is built on the research and expertise of our renowned scientists from MIT and their dedication to cutting edge orthopedic research. In particular, Dr. Alan Grodzinsky’s research into cartilage defects and cartilage tissue engineering holds promise for cartilage damage, where there exist no good therapies today.”

“Recent work by Dr. Robert Mauck, in Rocky Tuan’s research laboratory at the National Institutes of Health, has shown similarly strong cartilage tissue engineering results from multiple human mesenchymal stem cell (hMSC) donors. We believe that this holds important implications for the use of PuraMatrix in osteochondral defect surgical intervention as well as cartilage ex-vivo engineering.

Alan Grodzinsky, Sc.D., co-founder of 3DM and Director of the Center for Biomedical Engineering at the Massachusetts Institute of Technology, will step in as President-Elect of the Orthopedic Research Society in 2006.

References:
Mauck RL, Helm JM, Tuan RS. Enhanced Chondrogenesis and Development of Mechanical Properties of Human Mesenchymal Stem Cells Seeded in a Self-Assembling Peptide Hydrogel. Summer Bioengineering Conference, Vail, CO. (2005).

http://www.x-cd.com/sbc05/abstracts/b0278485.pdf

Kisiday, J., Jin, M., Kurz, B., Hung, H., Semino, C., Zhang, S. & Grodzinsky, A.J. Self-assembling peptide hydrogel fosters chondrocyte extracellular matrix production and cell division: implications for cartilage tissue repair. Proc. Natl. Acad. Sci. USA 99, 9996-1001 (2002).

About PuraMatrix
PuraMatrix Synthetic Peptide Hydrogels are the best-selling synthetic scaffolds for cell culture and bioproduction research, and have won numerous scientific awards. PuraMatrix gels consist of smart polymers, self-assembling in cell culture or in vivo to create biocompatible nanofiber scaffolds to facilitate healthy cell growth and tissue regeneration. PuraMatrix is currently in animal testing for orthopedics, cardiac and other medical device and drug delivery applications. PuraMatrix is used by most of the leading pharmaceutical, biotechnology and academic laboratories and has been featured in over twenty premier scientific journal publications. R&D Magazine recently awarded PuraMatrix its 42nd annual R&D 100 Prize as one of the most significant new products to impact life science and medical research.

About 3DM Inc.
3DM is a privately-held specialty biomaterials and medical device company headquartered in Cambridge, Massachusetts. 3DM has partnered with BD Biosciences for marketing PuraMatrix worldwide to the life science research and drug discovery communities. 3DM is further developing their self-assembling peptide hydrogels as medical devices in orthopedics, cardiovascular therapies and drug delivery applications. The patented technology, exclusively licensed from Massachusetts Institute of Technology, was pioneered at MIT through the work and expertise of Drs. Shuguang Zhang, Alan Grodzinsky, Robert Langer, Alexander Rich, Carlos Semino and Lisa Spirio.

Source: 3DM Inc.
               puramatrix.com

Contact: Zen Chu , President
                877-430-9595 contact@puramatrix.com